The 2026 Healthtech Messaging Index
Cleerly
cleerlyhealth.com·scored August 23, 2026
14/38
Weak
The signal is faint. Most of this page is about Cleerly, not the buyer, and AI has little it can repeat. There's a lot of room to move.
The page we scored
The AI Recommendation Check
When we asked AI who to recommend for AI-powered coronary artery disease (CAD) analysis software for CCTA imaging, it named:
Buyer we put in the prompt: Cardiologist or radiologist at a hospital, health system, or outpatient imaging center evaluating AI-powered cardiac imaging analysis tools. Both the buyer and the category were inferred from Cleerly’s homepage alone. The model had no web access.
Cleerly was on the list.
AI named them for their own category. That's the signal every homepage is supposed to send.
AI named you when asked who it recommends for "AI-powered coronary artery disease (CAD) analysis software for CCTA imaging", and described you accurately: "Cleerly is an AI platform focused on analyzing CCTA images to quantify coronary plaque burden and composition, enabling non-invasive CAD risk stratification.". Your positioning is landing with the machines.
Overall assessment
Cleerly's biggest strength is its clinical validation depth ... real trial names (CREDENCE, PACIFIC), specific comparator benchmarks, and named product modules (Cleerly ISCHEMIA) give it more evidentiary substance than most healthtech homepages. The biggest gap is the complete absence of a buyer-centric narrative: the page never names the problem, never shows a customer's voice or logo, never articulates the cost of inaction, and never paints a vivid 'after' state ... making it a feature catalog rather than a story that converts.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
02Rebellion / Movement
“No named enemy, no named status quo, no named industry pattern being challenged anywhere on the page.”
Cleerly takes no adversarial stance ... there is no named villain (e.g., stress testing, invasive procedures, missed diagnoses) being pushed against, making this purely product-descriptive rather than missionary.
All 19 signals, scored 0 to 2.
Total 14/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“Diagnose CAD earlier with AI-enhanced CCTA analysis”
The hero communicates what it does and loosely who it's for (providers), but a layperson cannot instantly grasp the problem, the audience, or the point of view without reading further.
- 0
02Rebellion / Movementweakest
“No named enemy, no named status quo, no named industry pattern being challenged anywhere on the page.”
Cleerly takes no adversarial stance ... there is no named villain (e.g., stress testing, invasive procedures, missed diagnoses) being pushed against, making this purely product-descriptive rather than missionary.
- 1
03Owned Language & Category
“Cleerly ISCHEMIA" and "PREVIEW" appear as named product terms.”
Cleerly names its own product modules (Cleerly ISCHEMIA, PREVIEW) but does not coin a broader category frame or owned terminology that an AI would quote back as a category definition.
- 1
04ICP Clarity
“I am a... Medical Provider / Patient”
The page splits between providers and patients but never specifies role (cardiologist, radiologist?), practice size, or setting, leaving ICP identification incomplete.
- 0
05Problem Leadership
“Get AI-powered insights on: Stenosis / Plaque volume / Plaque phenotype / Ischemia likelihood”
The page leads immediately with the solution and its features, never naming the buyer's problem or pain before pivoting to what Cleerly does.
- 1
06Solution Clarity
“Cleerly is a comprehensive, AI-driven platform that quantifies and assesses coronary artery disease (CAD) to deliver clinically actionable insights”
A visitor can form a rough one-sentence description, but the dense clinical language and feature list make it harder to repeat simply than it should be.
- 0
07Cost of Inaction
“No mention of what happens if CAD goes undetected, missed diagnoses, delayed treatment, or cost of inaction anywhere on the page.”
The page never names the stakes of not adopting Cleerly ... no patient mortality framing beyond one stat buried in a patient section, no revenue or liability consequence for providers.
- 1
08Promised Land
“potentially reducing the need for additional testing and enhancing diagnostic confidence”
There is a vague 'after' state (fewer tests, more confidence) but it is hedged with 'potentially' and never painted as a vivid, specific outcome the buyer will live in.
Trust Signal
4 signals
- 1
09Proof & Evidence
“higher diagnostic accuracy and area under the curve compared to FFRCT and stress testing, as referenced to 868 invasive measurements”
Clinical trial data (CREDENCE, PACIFIC) provides real numbers, but there are no before/after deltas for practice workflow, no time savings, no patient outcome improvements expressed in concrete operational terms.
- 0
10Social Proof
“No customer logos, no named testimonials with title and company, no case studies with named customers anywhere on the page.”
The page shows awards badges but zero social proof from actual paying customers ... no quotes, no names, no logos.
- 1
11Authority & Credibility
“Awards shown: "Digital Health Best in Class," "AI Breakthrough Award Best Overall," "Fierce 15 Award," "Digital Health 150”
Multiple industry awards are present and the CREDENCE/PACIFIC trial references add clinical credibility, but no founder credentials, original research authorship, or named experts are cited on the page.
- 0
12Alternatives Acknowledged
“No mention of competitors, alternative approaches, or the 'do nothing' option anywhere on the page.”
The page never acknowledges that buyers could choose FFRCT alone, stress testing, or incumbents ... alternatives are invisible despite being referenced obliquely in trial data.
AI Signal
6 signals
- 1
13Customer Focus
“Schedule a one-on-one product demo to see the benefits of Cleerly for your patients & practice”
The page oscillates between describing Cleerly's platform capabilities and gesturing at patient outcomes, but the protagonist is predominantly the product rather than the provider or patient living a transformed life.
- 1
14AI-Parmesan Index
“Get AI-powered insights on: Stenosis / Plaque volume / Plaque phenotype / Ischemia likelihood”
AI is claimed in the hero but the mechanistic explanation (machine learning variables, plaque quantification) is buried in body copy ... the hero-level AI claim is vague while substance exists but requires reading.
- 1
15LLM Quotability
“Cleerly ISCHEMIA demonstrated higher diagnostic accuracy and area under the curve compared to FFRCT and stress testing”
The clinical trial sentences are close to quotable but are embedded in dense technical context without a clean, standalone declarative sentence an LLM could lift as a recommendation.
- 0
16Copyright Freshness
“No visible dates on blog posts, case studies, or any content; no copyright year visible in the scraped content.”
The scraped page contains zero date stamps on any content, making it impossible for AI or human visitors to assess recency.
- 1
17Entity Distinctiveness
“Cleerly ISCHEMIA was the only non-invasive ischemia test that was prognostic of future MACE events”
The CREDENCE and PACIFIC trial differentiation is distinctive, but the overall homepage description ('AI-driven platform that quantifies and assesses CAD') could describe multiple competitors without the logo.
- 2
18AI Recommendation Check
“AI described you as: "Cleerly is an AI platform focused on analyzing CCTA images to quantify coronary plaque burden and composition, enabling non-invasive CAD risk stratification.”
AI named you when asked who it recommends for "AI-powered coronary artery disease (CAD) analysis software for CCTA imaging", and described you accurately: "Cleerly is an AI platform focused on analyzing CCTA images to quantify coronary plaque burden and composition, enabling non-invasive CAD risk stratification.". Your positioning is landing with the machines.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“[Request a Demo]" appears multiple times; "[See the Cleerly Difference]" as secondary CTA.”
There is a primary CTA (Request a Demo) repeated prominently, but there is no visible numbered process showing how a provider gets started, and the secondary CTA ('See the Cleerly Difference') is not a soft nurture path ... it links to a demo as well.
Keep the lead
AI already names Cleerly. The next edition decides if it still does.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Cleerly the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.